脐带血辅助单倍体外周血干细胞移植与无关供者外周血干细胞移植治疗恶性血液病的疗效比较
目的:比较脐带血辅助单倍体外周血干细胞移植（haplo-cord-PBSCT）与无关供者外周血干细胞移植（UD-PBSCT）治疗恶性血液病的疗效。方法:对中南大学湘雅医院2016年1月至2021年12月的104例接受haplo-cord-PBSCT和52例接受UD-PBSCT）的恶性血液病患者进行回顾性分析。结果:①haplo-cord-PBSCT和UD-PBSCT组中性粒细胞中位植入时间分别为13（9～22）d、13（10～24）d（ P＝0.834），血小板植入中位时间分别为15（7～103）d、14（8～38）d（ P＝0.816）。haplo-cord-PBSCT组和UD-PBSCT组...
Saved in:
| Published in | 中华血液学杂志 Vol. 45; no. 2; pp. 141 - 147 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | Chinese |
| Published |
中南大学湘雅医院血液内科，国家老年疾病临床医学研究中心（湘雅医院），湖南省血液肿瘤研究中心，长沙 410008
14.02.2024
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0253-2727 |
| DOI | 10.3760/cma.j.cn121090-20230928-00149 |
Cover
| Abstract | 目的:比较脐带血辅助单倍体外周血干细胞移植（haplo-cord-PBSCT）与无关供者外周血干细胞移植（UD-PBSCT）治疗恶性血液病的疗效。方法:对中南大学湘雅医院2016年1月至2021年12月的104例接受haplo-cord-PBSCT和52例接受UD-PBSCT）的恶性血液病患者进行回顾性分析。结果:①haplo-cord-PBSCT和UD-PBSCT组中性粒细胞中位植入时间分别为13（9～22）d、13（10～24）d（
P＝0.834），血小板植入中位时间分别为15（7～103）d、14（8～38）d（
P＝0.816）。haplo-cord-PBSCT组和UD-PBSCT组移植后30 d中性粒细胞累积植入率均为100.0%（
P＝0.314），移植后100 d血小板累积植入率分别为95.2%（95%
CI 88.3%～98.1%）、100.0%（
P＝0.927）。移植后30 d两组患者均达到完全供者嵌合状态，未发生脐带血干细胞植入。②haplo-cord-PBSCT组与UD-PBSCT组移植后100 d内Ⅱ～Ⅳ度急性GVHD的累积发生率分别为29.1%（95%
CI 20.1%～38.1%）、28.8%（95%
CI 17.2%～41.6%（
P＝0.965），Ⅲ/Ⅳ度急性GVHD的累积发生率分别为7.8%（95%
CI 3.6%～14.0%）、9.6%（95%
CI 3.5%～19.5%）（
P＝0.725）。haplo-cord-PBSCT组与UD-PBSCT组2年慢性GVHD的累积发生率分别为45.3%（95%
CI 36.1%～56.1%）、35.1%（95%
CI 21.6%～44.1%）（
P＝0.237），移植后2年重度慢性GVHD的累积发生率分别为13.6%（95%
CI 7.6%～21.3%）、12.9%（95%
CI 5.1%～24.3%）（
P＝0.840）。③haplo-cord-PBSCT组、UD-PBSCT组移植后2年CIR分别为12.8%（95%
CI 7.0%～20.5%）、10.0%（95%
CI 3.6%～20.2%）（
P＝0.341），NRM分别为14.7%（95%
CI 8.4%～22.6%）、16.2%（95%
CI 7.4%～28.0%）（
P＝0.681）。④haplo-cord-PBSCT组、UD-PBSCT组移植后2年OS率分别为82.2% |
|---|---|
| AbstractList | 目的:比较脐带血辅助单倍体外周血干细胞移植（haplo-cord-PBSCT）与无关供者外周血干细胞移植（UD-PBSCT）治疗恶性血液病的疗效。方法:对中南大学湘雅医院2016年1月至2021年12月的104例接受haplo-cord-PBSCT和52例接受UD-PBSCT）的恶性血液病患者进行回顾性分析。结果:①haplo-cord-PBSCT和UD-PBSCT组中性粒细胞中位植入时间分别为13（9～22）d、13（10～24）d（
P＝0.834），血小板植入中位时间分别为15（7～103）d、14（8～38）d（
P＝0.816）。haplo-cord-PBSCT组和UD-PBSCT组移植后30 d中性粒细胞累积植入率均为100.0%（
P＝0.314），移植后100 d血小板累积植入率分别为95.2%（95%
CI 88.3%～98.1%）、100.0%（
P＝0.927）。移植后30 d两组患者均达到完全供者嵌合状态，未发生脐带血干细胞植入。②haplo-cord-PBSCT组与UD-PBSCT组移植后100 d内Ⅱ～Ⅳ度急性GVHD的累积发生率分别为29.1%（95%
CI 20.1%～38.1%）、28.8%（95%
CI 17.2%～41.6%（
P＝0.965），Ⅲ/Ⅳ度急性GVHD的累积发生率分别为7.8%（95%
CI 3.6%～14.0%）、9.6%（95%
CI 3.5%～19.5%）（
P＝0.725）。haplo-cord-PBSCT组与UD-PBSCT组2年慢性GVHD的累积发生率分别为45.3%（95%
CI 36.1%～56.1%）、35.1%（95%
CI 21.6%～44.1%）（
P＝0.237），移植后2年重度慢性GVHD的累积发生率分别为13.6%（95%
CI 7.6%～21.3%）、12.9%（95%
CI 5.1%～24.3%）（
P＝0.840）。③haplo-cord-PBSCT组、UD-PBSCT组移植后2年CIR分别为12.8%（95%
CI 7.0%～20.5%）、10.0%（95%
CI 3.6%～20.2%）（
P＝0.341），NRM分别为14.7%（95%
CI 8.4%～22.6%）、16.2%（95%
CI 7.4%～28.0%）（
P＝0.681）。④haplo-cord-PBSCT组、UD-PBSCT组移植后2年OS率分别为82.2% |
| Abstract_FL | Objectives:To assess the efficacy of cord blood-assisted haploid peripheral blood stem cell transplantation (haplo-cord-PBSCT) versus unrelated donor peripheral blood stem cell transplantation (UD-PBSCT) in the treatment of malignant hematological diseases.Methods:A retrospective analysis was performed on one hundred and four patients with malignant hematological diseases who underwent haplo-cord-PBSCT and fifty-two patients who underwent UD-PBSCT at Xiangya Hospital of Central South University between January 2016 and December 2021.Results:①The median implantation time for neutrophils in the haplo-cord-PBSCT and UD-PBSCT groups was 13 (9–22) days and 13 (10–24) days, respectively (
P=0.834), whereas the median implantation time for platelets was 15 (7–103) days and 14 (8-38) days, respectively (
P=0.816). The cumulative implantation rate of neutrophils at 30 days after transplantation in the haplo-cord-PBSCT group and the UD-PBSCT group was 100% (
P=0.314), and the cumulative platelet implantation rate at 100 days after transplantation was 95.2% (95%
CI 88.3% - 98.1% ) and 100% (
P=0.927), respectively. 30 days after transplantation, both groups of patients achieved complete donor chimerism, and no umbilical cord blood stem cells were implanted. ②The cumulative incidence rates of grade Ⅱ-Ⅳ acute GVHD within 100 days after transplantation in the haplo-cord-PBSCT group and the UD-PBSCT group were 29.1% (95%
CI 20.1% –38.1% ) and 28.8% (95%
CI 17.2% –41.6% (
P=0.965), respectively. The cumulative incidence rates of grade Ⅲ/Ⅳ acute GVHD were 7.8% (95%
CI 3.6% –14.0% ) and 9.6% (95%
CI 3.5% –19.5% ) (
P=0.725). The cumulative incidence rates of 2-year chronic GVHD in the haplo-cord-PBSCT group and the UD-PBSCT group were 45.3% (95%
CI 36.1% -56.1% ) and 35.1% (95%
CI 21.6% –44.1% ), respectively (
P=0.237). The cumulative incidence rates of severe chronic GVHD at 2 years after transplantation were 13.6% (95%
CI 7.6% -21.3% ) and 12.9% (95%
CI 5.1% -24.3% ), respectively (
P=0.840). ③The 2-year CIR after transplantation in the haplo-cord-PBSCT group and UD-PBSCT group were 12.8% (95% CI 7.0% –20.5% ) and 10.0% (95%
CI 3.6% –20.2% ), respectively (
P=0.341), and the NRM were 14.7% (95%
CI 8.4% –22.6% ) and 16.2% (95%
CI 7.4% –28.0% ), respectively (
P=0.681). ④The 2-year OS rates in the haplo-cord-PBSCT and UD-PBSCT groups after transplantation were 82.2% (95%
CI 74.8% –90.3% ) and 75.5% (95%
CI 64.2% -88.7% ), respectively (
P=0.276). The 2-year DFS rates were 69.9% (95%
CI 61.2% –79.8% ) and 73.8% (95%
CI 62.4% -87.3% ), respectively (
P=0.551). The 2-year rates of GVHD-free/recurrence-free survival (GRFS) were 55.3% (95%
CI 44.8% -64.8% ) and 64.7% (95%
CI 52.8% –79.3% ), respectively (
P=0.284) .
Conclusion:The findings of this study indicate that haplo-cord-PBSCT and UD-PBSCT have comparable efficacy and safety in the treatment of malignant hematological diseases and can be used as an alternative treatment options. |
| Author | 马霞 陈旭 王诗宇 徐雅靖 刘弋 陈焱 华娟 曾枞 程婷婷 |
| AuthorAffiliation | 中南大学湘雅医院血液内科，国家老年疾病临床医学研究中心（湘雅医院），湖南省血液肿瘤研究中心，长沙 410008 |
| AuthorAffiliation_xml | – name: 中南大学湘雅医院血液内科，国家老年疾病临床医学研究中心（湘雅医院），湖南省血液肿瘤研究中心，长沙 410008 |
| Author_FL | Cheng Tingting Chen Xu Liu Yi Wang Shiyu Zeng Cong Chen Yan Xu Yjing Hua Juan Ma Xia |
| Author_FL_xml | – sequence: 1 fullname: Ma Xia – sequence: 2 fullname: Chen Yan – sequence: 3 fullname: Liu Yi – sequence: 4 fullname: Cheng Tingting – sequence: 5 fullname: Chen Xu – sequence: 6 fullname: Zeng Cong – sequence: 7 fullname: Hua Juan – sequence: 8 fullname: Wang Shiyu – sequence: 9 fullname: Xu Yjing |
| Author_xml | – sequence: 1 fullname: 马霞 – sequence: 2 fullname: 陈焱 – sequence: 3 fullname: 刘弋 – sequence: 4 fullname: 程婷婷 – sequence: 5 fullname: 陈旭 – sequence: 6 fullname: 曾枞 – sequence: 7 fullname: 华娟 – sequence: 8 fullname: 王诗宇 – sequence: 9 fullname: 徐雅靖 |
| BookMark | eNp1kM1Kw0AcxPdQwbb6GHpL_e9ukm2OUvyCghc9l83HKkVTMIhVL5E2IkJF0bagIArF6kmoUCrFPk13k8cwoldPAzM_ZmByKOPXfA-hBQwFykxYcvZ5oVpwfEwwWKARIBQsUtQAsG5lUBaIQTXCCJtFuSCoAugkTbLoNGley9FL8hwmk0hevslWW4at6det7HXkzWvqy89BPD5PGo9xf6x6renoSnWfZPQxnTwkYfQfpgbjuNNVZ0MV9tNUDQdxN4rvmz9m-0K93yWTxhyaEXwv8Ob_NI-2V1e2SutaeXNto7Rc1gIMmGm0yLFhUqETx-SCFl3h2jZQ1_U4JbrLbMwFEGED2CazuDA86jAHUtSkFFyH5tHib-8R9wX3dyrV2uGBny5WTnbrx_X0Kx0IAKPfIguP6Q |
| ContentType | Journal Article |
| Copyright | Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| Copyright_xml | – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| DBID | 2B. 4A8 92I 93N PSX TCJ |
| DOI | 10.3760/cma.j.cn121090-20230928-00149 |
| DatabaseName | Wanfang Data Journals - Hong Kong WANFANG Data Centre Wanfang Data Journals 万方数据期刊 - 香港版 China Online Journals (COJ) China Online Journals (COJ) |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| DocumentTitle_FL | Haploidentical donor peripheral blood stem cell transplantation using third-party cord blood compared with matched unrelated donor transplantation for patients with hematologic malignancies |
| EndPage | 147 |
| ExternalDocumentID | zhxyx202402007 |
| GrantInformation_xml | – fundername: 国家自然科学基金; National Natural Science Foundation of China funderid: (81974002); (81974002) |
| GroupedDBID | --- -05 2B. 4A8 92F 92I 93N ABJNI ACGFS ALMA_UNASSIGNED_HOLDINGS CCEZO CIEJG CW9 F5P OK1 PSX RPM TCJ TGQ U1G U5O |
| ID | FETCH-LOGICAL-s1017-38a1563f42c6af38dfdbb03ddea324d7b1af02fb00b679af5e3c7c0af36330dc3 |
| ISSN | 0253-2727 |
| IngestDate | Thu May 29 04:11:39 EDT 2025 |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Haploidentical hematopoietic stem cell transplantation 脐带血 Umbilical cord blood Unrelated donor hematopoietic stem cell transplantation 无关供者造血干细胞移植 单倍体造血干细胞移植 |
| Language | Chinese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-s1017-38a1563f42c6af38dfdbb03ddea324d7b1af02fb00b679af5e3c7c0af36330dc3 |
| PageCount | 7 |
| ParticipantIDs | wanfang_journals_zhxyx202402007 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-02-14 |
| PublicationDateYYYYMMDD | 2024-02-14 |
| PublicationDate_xml | – month: 02 year: 2024 text: 2024-02-14 day: 14 |
| PublicationDecade | 2020 |
| PublicationTitle | 中华血液学杂志 |
| PublicationTitle_FL | Chinese Journal of Hematology |
| PublicationYear | 2024 |
| Publisher | 中南大学湘雅医院血液内科，国家老年疾病临床医学研究中心（湘雅医院），湖南省血液肿瘤研究中心，长沙 410008 |
| Publisher_xml | – name: 中南大学湘雅医院血液内科，国家老年疾病临床医学研究中心（湘雅医院），湖南省血液肿瘤研究中心，长沙 410008 |
| SSID | ssj0042014 ssib051368330 ssib001103535 ssib058574913 |
| Score | 2.4043312 |
| Snippet | 目的:比较脐带血辅助单倍体外周血干细胞移植（haplo-cord-PBSCT）与无关供者外周血干细胞移植（UD-PBSCT）治疗恶性血液病的疗效。方法:对中南大学湘雅医院2016年1月至2021... |
| SourceID | wanfang |
| SourceType | Aggregation Database |
| StartPage | 141 |
| Title | 脐带血辅助单倍体外周血干细胞移植与无关供者外周血干细胞移植治疗恶性血液病的疗效比较 |
| URI | https://d.wanfangdata.com.cn/periodical/zhxyx202402007 |
| Volume | 45 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAQN databaseName: PubMed Central issn: 0253-2727 databaseCode: RPM dateStart: 20150101 customDbUrl: isFulltext: true dateEnd: 99991231 titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ omitProxy: true ssIdentifier: ssj0042014 providerName: National Library of Medicine |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Na9RAFA-lBfEiiorf9uActyaZfMwcJ9spxYOnFnorSTaxCK5gK9T1stKuiFBRtC0oiEKxehIqlEqxf02zu3-G781kN-mH2kovYXjz5s1v3u8x-2Z2MjGMW65rJ27MzYqd-m7F4bFf4REsVtIkMq2YhrAsUqd873rjk86dKXdqYKhRfrtkLhqJG4e-V_I_rIIMeMW3ZI_BbN8oCKAM_MITGIbnkTgmkhHmEG4S6ZKAEeGhRFh4fAEKgSTMxSomiOCqMEq4lphYlg4JQEJRIsCOhwVuEcFKdsAyJ4FNpE-CgDDVBaOES5QIJZQeNs8NQq1ECYda1RwwBFRVScID1dzMgZ1Mpx5qosRHa9AvSJhFAk8VTNQvLHso15ZBE2FAQaAby83BS4ypLsYId3rOpOVUPh-sGM0di6M-2IuLCkIh4aCjJAHY7P_8E8mRHFHFAq_CEMs1nCscPuILrKJGweNMWasSFhQ1PjqSBapncKHfL5T3d2wHj4Rbxf7u_sFwP6dH-HvGAKxgrxyJzGOrqlyvoAr7cBcAf9rRYA2YlmMKdFURH2AIYhdSEaaDw-pFQI-VQJYIU1CxCnQEBncBow9VBR9XzXH03p4BAgEQTDkMdrRxaWVeAq9beSWP-Ugggj_oBIbcQ7-ow9Cxx0CoQ0MJdawDJEmVo0wH_zkrpRawuKAV29c3YfRyD32Vaj7H2qVEwtLXweU5qaVvpd2f7uCBNpij4gfhyP2RuI53AeKsi9sKHC-ex-2PIs_rn75tzMw_mcdQM_VFHEM2ZETmvp1OWBZQt1hKuRb1GC22Glzm-o464aCzXgcWEuqqvt4oTxkkR3j7r_jUy5L1NKzfK-X1E2eNM_mCfFjo2fWcMdCYOW887S6-zra-dD83uzut7OW3bGk5ay7t_nqbra1kb76CPPu50dl-3l342Fnfbq8t7W69aq9-ylo_dnc-dJutP6m1N7Y7K6vtZ5vt5jrUtjc3OqutzvtFFC6_aH9_191ZuGBMjsmJ6ngl_0xNZRbzmQploeV6NHXs2AtTymppLYpMCnljCKvVmh9ZYWraKfg08nwepm5CYz82QdUDh9ZietEYrD-sJ5eMYZvFSS2pMWgWO0lsR66H37-AHEldIpteNm7mzprOf4Zmp_eyeeWfGleN08U0c80YnHv0OLkOC6u56IaKgN9XER73 |
| linkProvider | National Library of Medicine |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E8%84%90%E5%B8%A6%E8%A1%80%E8%BE%85%E5%8A%A9%E5%8D%95%E5%80%8D%E4%BD%93%E5%A4%96%E5%91%A8%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E4%B8%8E%E6%97%A0%E5%85%B3%E4%BE%9B%E8%80%85%E5%A4%96%E5%91%A8%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E%E7%A7%BB%E6%A4%8D%E6%B2%BB%E7%96%97%E6%81%B6%E6%80%A7%E8%A1%80%E6%B6%B2%E7%97%85%E7%9A%84%E7%96%97%E6%95%88%E6%AF%94%E8%BE%83&rft.jtitle=%E4%B8%AD%E5%8D%8E%E8%A1%80%E6%B6%B2%E5%AD%A6%E6%9D%82%E5%BF%97&rft.au=%E9%A9%AC%E9%9C%9E&rft.au=%E9%99%88%E7%84%B1&rft.au=%E5%88%98%E5%BC%8B&rft.au=%E7%A8%8B%E5%A9%B7%E5%A9%B7&rft.date=2024-02-14&rft.pub=%E4%B8%AD%E5%8D%97%E5%A4%A7%E5%AD%A6%E6%B9%98%E9%9B%85%E5%8C%BB%E9%99%A2%E8%A1%80%E6%B6%B2%E5%86%85%E7%A7%91%EF%BC%8C%E5%9B%BD%E5%AE%B6%E8%80%81%E5%B9%B4%E7%96%BE%E7%97%85%E4%B8%B4%E5%BA%8A%E5%8C%BB%E5%AD%A6%E7%A0%94%E7%A9%B6%E4%B8%AD%E5%BF%83%EF%BC%88%E6%B9%98%E9%9B%85%E5%8C%BB%E9%99%A2%EF%BC%89%EF%BC%8C%E6%B9%96%E5%8D%97%E7%9C%81%E8%A1%80%E6%B6%B2%E8%82%BF%E7%98%A4%E7%A0%94%E7%A9%B6%E4%B8%AD%E5%BF%83%EF%BC%8C%E9%95%BF%E6%B2%99%E3%80%80410008&rft.issn=0253-2727&rft.volume=45&rft.issue=2&rft.spage=141&rft.epage=147&rft_id=info:doi/10.3760%2Fcma.j.cn121090-20230928-00149&rft.externalDocID=zhxyx202402007 |
| thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzhxyx%2Fzhxyx.jpg |